



RECEIVED

FEB 08 2001

TECH CENTER 1600/2800

Express Mail No.: EL 168 272 512 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Karsenty et al.

Application No.: 09/489,873

Group Art Unit: 1643

Filed: January 20, 2000

Examiner: To Be Assigned

For: METHODS AND COMPOSITIONS
FOR CONTROL OF BONE
FORMATION VIA MODULATION OF
LEPTIN ACTIVITY

Attorney Docket No.: 9142-006-999

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.56 AND §1.97**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, attorneys for Applicants hereby direct the Examiner's attention to references AA through CN listed on the attached revised form PTO 1449. Legible copies of references AA through CN are submitted herewith. Applicants have grouped the references as follows: (1) references AA to AM, pertaining to leptin sequences, (2) references AN to BT, pertaining to uses of leptins, including binding compounds, (3) references BU to CG, pertaining to leptin receptor sequences, and (4) references CH to CN, pertaining to uses of leptin receptors, including binding compounds.

Identification of the above-listed references is not to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application. Consequently, Applicants respectfully decline to use form PTO-1449, since that form identifies all of the references cited therein as "Prior Art." As an alternative, Applicants submit herewith a "Revised Form PTO 1449" entitled "List of References Cited." Applicants respectfully request that the Examiner review the references

cited on the attached revised PTO Form 1449, and that the references be made of record in the file history of the instant application.

Pursuant to 37 C.F.R. § 1.97(b)(3), since this Information Disclosure Statement is believed to be filed before the mailing date of the first Office Action on the merits, no fee is believed to be due. However, should the Patent Office determine otherwise, please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed.

Respectfully submitted,

Date February 5, 2001

by

Samuel B. Abrams 30,605
Samuel B. Abrams (Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

Miriam C. Jayne
Feb. No. 39,201

Enclosure